←Fibromyalgia
Study register · detail Leitlinie · Fibromyalgia · 2018

European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management

Häuser et al. ·European Journal of Pain Impact 2.6
Unclear 189 citations
SampleLeitlinie
Blindingn.a.
DesignLeitlinie
Key finding

This is a guideline/position paper, not a clinical study with measurable treatment outcomes. Recommendations for the use of cannabis-based medicines in chronic pain are given, but no specific effect measures are reported.

Summary

EFIC position paper on the appropriate use of cannabis-based medicines in chronic pain; recommends cautious use in fibromyalgia due to limited evidence (weak recommendation).

SummaryEFIC expert consensus on the appropriate use of cannabis-based medicines in chronic pain — recommendation only by experienced clinicians, as part of multimodal therapy, after failure of first-/second-line therapies. Moderate evidence for neuropathic pain, individual treatment trials for other chronic pain entities under close monitoring.
Quality profile
Sample size —
Blinding —
Effect size —
Citations / year ★★★★★
Authors
Häuser W, Finn D P, Kalso E et al.
DOI 10.1002/ejp.1297↗
Design: Leitlinie
Share
Abstract
Significance: This position paper provides expert recommendations for nonspecialist and specialist healthcare professionals in Europe, on the importance and the appropriate use of cannabis-based medicines as part of a multidisciplinary approach to pain management, in properly selected and supervised patients.
Indication
Further studies on Fibromyalgia
All studies →
S Rasmussen et al. · 2026 · Annals of the rheumatic diseases
1 citations
Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Harm RCT

n=200 Fibromyalgie-Patienten, CBD 50 mg täglich vs. Placebo über 24 Wochen; primärer Endpunkt Schmerzintensität (NRS): CBD-Gruppe -0,4 Punkte (95% CI: -0,82 bis 0,08), Placebo-Gruppe -1,1 Punkte (95% CI: -1,53 bis -0,63), Gruppenunterschied -0,7 Punkte (95% CI: -1,2 bis -0,25; p=0,0028) zugunsten Placebo. CBD 50 mg täglich zeigte keine analgetische Wirksamkeit.

10.1016/j.ard.2025.07.008 View study →
S Walitt et al. · 2016 · Cochrane Database of Systematic Reviews
120 citations
Cannabinoids for fibromyalgia
No benefit demonstrated Cochrane Review

Cochrane SR über 2 RCTs (n=72) zu Cannabinoiden bei Fibromyalgie; nabilone vs. Placebo zeigte keine statistisch signifikante Schmerzreduktion oder Verbesserung der Lebensqualität; sehr kleine Stichprobengröße und kurze Studiendauer limitieren Aussagekraft; keine ausreichende Evidenz für Wirksamkeit.

10.1002/14651858.cd011694.pub2 View study →
S Moore et al. · 2025 · Rheumatology (Oxford, England)
15 citations
Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews.
Mixed Systematic Review

Umbrella Review über k=21 Cochrane Reviews zu pharmakologischer Fibromyalgie-Therapie (87 Trials, n=17.631). Für Cannabinoide: limitierte und inadäquate Datenlage identifiziert — keine ausreichende Evidenz für Wirksamkeit. Duloxetin, Milnacipran und Pregabalin zeigten moderate/gute Evidenz für substanzielle Schmerzreduktion (≥50%) bei etwa 1 von 10 Erwachsenen über 4-12 Wochen.

10.1093/rheumatology/keae707 View study →

The impediment to action advances action. — Marcus Aurelius